LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 2418

Search options

  1. Article ; Online: Managed care opportunities and approaches to select treatment for sight preservation.

    Liu, YuQian

    The American journal of managed care

    2022  Volume 28, Issue 3 Suppl, Page(s) S44–S51

    Abstract: Anti-vascular endothelial growth factor therapies have become the mainstay of treatment for both diabetic macular edema and neovascular age-related macular degeneration. This treatment is imperative for vision preservation including visual acuity. ... ...

    Abstract Anti-vascular endothelial growth factor therapies have become the mainstay of treatment for both diabetic macular edema and neovascular age-related macular degeneration. This treatment is imperative for vision preservation including visual acuity. However, treatment burdens include high costs, frequent injections, continued visual loss, and loss of ability to perform day-to-day functions. Although clinical trial data have provided insights to treatment options and protocols, real-world patient experiences and adherence to therapies do not often mimic clinical trials as patients cannot fully adhere to their treatment schedule, leading to poor disease outcomes. Payers may consider various strategies such as step therapies, fee schedule management, and driving utilization through specialty pharmacies to contain costs. However, it is important to recognize not all patients will respond to a one-size-fits-all approach to treatment, warranting a more personalized approach.
    MeSH term(s) Angiogenesis Inhibitors ; Diabetic Retinopathy/therapy ; Humans ; Intravitreal Injections ; Macular Degeneration/drug therapy ; Macular Edema/drug therapy ; Managed Care Programs ; Ranibizumab/therapeutic use ; Vascular Endothelial Growth Factor A ; Wet Macular Degeneration/drug therapy
    Chemical Substances Angiogenesis Inhibitors ; Vascular Endothelial Growth Factor A ; Ranibizumab (ZL1R02VT79)
    Language English
    Publishing date 2022-03-11
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2035781-3
    ISSN 1936-2692 ; 1088-0224 ; 1096-1860
    ISSN (online) 1936-2692
    ISSN 1088-0224 ; 1096-1860
    DOI 10.37765/ajmc.2022.88854
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Uptake of oncology biosimilars: managed care strategies to improve value-based care systems.

    Liu, YuQian

    The American journal of managed care

    2022  Volume 28, Issue 5 Suppl, Page(s) S91–S97

    Abstract: The use of biosimilars in oncology and as supportive agents for patients with cancer has introduced an important opportunity to expand access to cost-effective care, but their utilization remains inconsistent and is influenced by a variety of factors. ... ...

    Abstract The use of biosimilars in oncology and as supportive agents for patients with cancer has introduced an important opportunity to expand access to cost-effective care, but their utilization remains inconsistent and is influenced by a variety of factors. Promoting the uptake of biosimilars across healthcare systems relies on improving perception and education about biosimilars, which involves multiple stakeholders, including pharmacists, providers, and patients. Clinicians and managed care professionals must consider comparative analytical studies, clinical efficacy data, and reductions in costs of care associated with biosimilars when establishing protocols for their inclusion within formularies. Real-world switch studies in oncology biosimilars that have demonstrated bioequivalence provide basis to support efficacy and safety to transition to a biosimilar product. Incorporating oncology biosimilars into treatment pathways will be an important next step in providing value-based care to patients with cancer.
    MeSH term(s) Biosimilar Pharmaceuticals/therapeutic use ; Humans ; Managed Care Programs ; Medical Oncology/methods ; Neoplasms/drug therapy ; Pharmacists
    Chemical Substances Biosimilar Pharmaceuticals
    Language English
    Publishing date 2022-09-01
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2035781-3
    ISSN 1936-2692 ; 1088-0224 ; 1096-1860
    ISSN (online) 1936-2692
    ISSN 1088-0224 ; 1096-1860
    DOI 10.37765/ajmc.2022.89188
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Hepatic Arterial Infusion Chemotherapy for Unresectable HCC: Ready for Primetime?

    Yu, Qian / Ahmed, Osman

    Academic radiology

    2024  Volume 31, Issue 3, Page(s) 844–845

    MeSH term(s) Humans ; Carcinoma, Hepatocellular/drug therapy ; Liver Neoplasms/diagnostic imaging ; Liver Neoplasms/drug therapy ; Infusions, Intra-Arterial ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Hepatic Artery ; Treatment Outcome
    Language English
    Publishing date 2024-02-16
    Publishing country United States
    Document type Editorial
    ZDB-ID 1355509-1
    ISSN 1878-4046 ; 1076-6332
    ISSN (online) 1878-4046
    ISSN 1076-6332
    DOI 10.1016/j.acra.2024.02.018
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Utilizing oncology biosimilars to minimize the economic burden associated with cancer treatment: managed care considerations.

    Liu, YuQian

    The American journal of managed care

    2021  Volume 27, Issue 14 Suppl

    Abstract: The high cost of therapies for treatment of cancer places a substantial burden on the United States healthcare system. In recent years, there has been increased attention to the cost-savings benefits associated with clinical uptake of biosimilars and ... ...

    Abstract The high cost of therapies for treatment of cancer places a substantial burden on the United States healthcare system. In recent years, there has been increased attention to the cost-savings benefits associated with clinical uptake of biosimilars and their market availability, with several biosimilars with oncology-related indications currently available. Though the biosimilar development process has contributed to price reductions and increased patient access to care, misconceptions about biosimilar safety and efficacy as well as inconsistent prescribing patterns have emerged as main barriers to their use in clinical practice. However, this hesitation from a clinical standpoint is not necessarily matched by payers or formulary decision makers in the oncology space. Earlier detection of cancer and longer duration of therapy has spurred discussion about initiation of biosimilars for newly diagnosed patients requiring treatment, but incorporation of biosimilars into formularies and institution protocols remain a challenge. There is clear urgency within the healthcare system to initiate the inclusion of biosimilars into treatment pathways for cancer, and pharmacists who care for patients with cancer have an important role in providing consistent messaging to both healthcare professionals and patients about biosimilars.
    MeSH term(s) Biosimilar Pharmaceuticals/therapeutic use ; Cost of Illness ; Humans ; Managed Care Programs ; Medical Oncology ; Neoplasms/drug therapy ; United States
    Chemical Substances Biosimilar Pharmaceuticals
    Language English
    Publishing date 2021-08-13
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2035781-3
    ISSN 1936-2692 ; 1088-0224 ; 1096-1860
    ISSN (online) 1936-2692
    ISSN 1088-0224 ; 1096-1860
    DOI 10.37765/ajmc.2021.88734
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Syntheses, Crystal Structures, and Antibacterial Activity of New Tetranuclear Zinc(II) Complexes with Schiff Base Ligands

    Heng-Yu Qian

    Acta Chimica Slovenica, Vol 68, Iss 3, Pp 638-

    2021  Volume 644

    Abstract: Two new tetranuclear zinc(II) complexes, [Zn4(L1)2(μ2-η1:η1-CH3COO)4(μ1,1-N3)2] (1) and [Zn4(L2)4(CH3CH2OH)(H2O)] (2), where L1 and L2 are the deprotonated forms of 4-fluoro-2-((pyridin-2-ylmethylimino)methyl)phenol (HL1) and 4-fluoro-2-((2-( ... ...

    Abstract Two new tetranuclear zinc(II) complexes, [Zn4(L1)2(μ2-η1:η1-CH3COO)4(μ1,1-N3)2] (1) and [Zn4(L2)4(CH3CH2OH)(H2O)] (2), where L1 and L2 are the deprotonated forms of 4-fluoro-2-((pyridin-2-ylmethylimino)methyl)phenol (HL1) and 4-fluoro-2-((2-(hydroxymethyl)phenylimino)methyl)phenol (H2L2), have been synthesized and characterized by elemental analysis, IR and UV-vis spectroscopy, and single crystal X-ray diffraction. X-ray crystal structural study indicated that the distances between the adjacent Zn atoms are 3.160(1)–3.353(1) Å in 1 and 3.005(1)–3.168(1) Å in 2. All zinc atoms in 1 are pentacoordinated in trigonal bipyramidal geometry, and those in 2 are in square pyramidal and octahedral geometry. The complexes and the Schiff bases were assayed for antibacterial activities against three Gram-positive bacterial strains (B. subtilis, S. aureus, and St. faecalis) and three Gram-negative bacterial strains (E. coli, P. aeruginosa, and E. cloacae) by MTT method.
    Keywords tridentate schiff base ; crystal structure ; zinc complex ; tetranuclear structure ; antibacterial property ; Chemistry ; QD1-999
    Subject code 540
    Language English
    Publishing date 2021-09-01T00:00:00Z
    Publisher Slovenian Chemical Society
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  6. Article ; Online: Synthesis, Characterization and Crystal Structures of Zinc(II) and Cobalt(III) Complexes Derived from Tridentate NNO- and NON- Schiff Bases with Antibacterial Activities

    Heng-Yu Qian

    Acta Chimica Slovenica, Vol 68, Iss 3, Pp 700-

    2021  Volume 708

    Abstract: Two new polynuclear zinc complexes [Zn2Br2(L1)2] (1) and [Zn(μ1,5-dca)L2]n (2), and two new mononuclear cobalt(III) complexes [CoL1N3(Brsal)] (3) and [CoL2(HL2)] (4), where L1 = 5-bromo-2-(((2-dimethylamino)ethyl)imino)methyl)phenolate, L2 = 5-bromo-2-((( ...

    Abstract Two new polynuclear zinc complexes [Zn2Br2(L1)2] (1) and [Zn(μ1,5-dca)L2]n (2), and two new mononuclear cobalt(III) complexes [CoL1N3(Brsal)] (3) and [CoL2(HL2)] (4), where L1 = 5-bromo-2-(((2-dimethylamino)ethyl)imino)methyl)phenolate, L2 = 5-bromo-2-(((2-hydroxyethyl)imino)methyl)phenolate, dca = dicyanoamide, Brsal = 5-bromo-2-formylphenolate, have been synthesized and characterized. The complexes were characterized by elemental analyses, IR, UV-Vis spectra, molar conductivity, and single crystal X-ray diffraction. X-ray analysis indicates that the Zn atoms in complex 1 are in distorted square pyramidal coordination, the Zn atoms in complex 2 are in distorted trigonal bipyramidal coordination, and the Co atoms in complexes 3 and 4 are in octahedral coordination. The molecules of the complexes are stacked through π···π interactions and hydrogen bonds. The complexes were assayed for antibacterial activities against three Gram-positive bacterial strains (B. subtilis, S. aureus, and St. faecalis) and three Gram-negative bacterial strains (E. coli, P. aeruginosa, and E. cloacae) by MTT method.
    Keywords schiff base ; zinc complex ; cobalt complex ; x-ray diffraction ; antibacterial activity ; Chemistry ; QD1-999
    Subject code 540
    Language English
    Publishing date 2021-09-01T00:00:00Z
    Publisher Slovenian Chemical Society
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  7. Article ; Online: Transjugular Intrahepatic Portosystemic Shunt Placement: Entering the Era of Controlled Expansion.

    Ahmed, Osman / Yu, Qian

    Cardiovascular and interventional radiology

    2023  Volume 46, Issue 6, Page(s) 823–824

    MeSH term(s) Humans ; Portasystemic Shunt, Transjugular Intrahepatic ; Liver Cirrhosis ; Hepatic Encephalopathy
    Language English
    Publishing date 2023-05-03
    Publishing country United States
    Document type Editorial ; Comment
    ZDB-ID 603082-8
    ISSN 1432-086X ; 0342-7196 ; 0174-1551
    ISSN (online) 1432-086X
    ISSN 0342-7196 ; 0174-1551
    DOI 10.1007/s00270-023-03450-w
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article: Review of Air Embolism for the Interventional Radiologist

    Zangan, Steven M. / Yu, Qian

    The Arab Journal of Interventional Radiology

    2024  Volume 08, Issue 01, Page(s) 6–12

    Abstract: Air embolism is an uncommon but well-described complication of day-to-day interventional radiology procedures. When symptoms manifest, air embolism often results in severe morbidity or even death. Thus, an understanding of how to prevent, recognize, and ... ...

    Abstract Air embolism is an uncommon but well-described complication of day-to-day interventional radiology procedures. When symptoms manifest, air embolism often results in severe morbidity or even death. Thus, an understanding of how to prevent, recognize, and manage air embolism is imperative for interventional radiologists. This article reviews the pathophysiology, etiology, diagnosis and treatment, and prognosis of air embolism.
    Keywords air embolism ; interventional radiology ; adverse events ; complication ; review
    Language English
    Publishing date 2024-01-01
    Publisher Thieme Medical and Scientific Publishers Pvt. Ltd.
    Publishing place Stuttgart ; New York
    Document type Article
    ISSN 2542-7083 ; 2542-7075
    ISSN (online) 2542-7083
    ISSN 2542-7075
    DOI 10.1055/s-0043-1777810
    Database Thieme publisher's database

    More links

    Kategorien

  9. Article ; Online: Progress in application of mesenchymal stem cells in treatment of acute myocardial infarction

    JIANG Yu, QIAN Haiyan

    Jichu yixue yu linchuang, Vol 43, Iss 1, Pp 21-

    2023  Volume 29

    Abstract: Acute myocardial infarction (AMI) is an ischemic myocardial necrosis caused by coronary artery occlusion, which can't be self-repaired through cardiomyocyte regeneration. The necrotic myocardium is replaced by fibrous scars during ventricular remodeling, ...

    Abstract Acute myocardial infarction (AMI) is an ischemic myocardial necrosis caused by coronary artery occlusion, which can't be self-repaired through cardiomyocyte regeneration. The necrotic myocardium is replaced by fibrous scars during ventricular remodeling, ultimately leading to heart failure. The safety and efficacy of mesenchymal stem cells (MSCs) transplantation after AMI have been demonstrated by numerous preclinical and clinical studies. MSCs are composed of heterogeneous cells with multi-directional differentiation potential, which can regulate oxidative stress, and secrete a variety of cytokines and growth factors. After being implanted in vivo, MSCs play their roles in immunomodulatory, angiogenesis, anti-inflammatory, and anti-apoptosis through trans-differentiation, cell fusion, and paracrine. Currently, there has been a variety of access to implant MSCs, including intramyocardial injection, intracoronary infusion, and intravenous injection. In addition, the dose and timing of transplantation are also important factors affecting the therapeutic effect of MSCs. However, the low retention and survival rates of MSCs in infarcted myocardium after being transplanted limit their further effect and hinder their clinical translation. In recent years, new concepts, strategies, technologies, and methods for MSCs treatment have been proposed, including cell preconditioning, optimization of the infract local microenvironment, combined gene therapy or tissue engineering technology, exosome infusion, and targeted transplantation of stem cells and their exosomes, which significantly improve the transplantation efficiency and therapeutic effect of MSCs, and open a new chapter for the research and transformation of stem cells to repair the infarcted myocardium. This article reviews the progress of MSCs in repairing myocardial infarction in recent years.
    Keywords mesenchymal stem cells|myocardial infarction|exosome ; Medicine ; R
    Subject code 610
    Language Chinese
    Publishing date 2023-01-01T00:00:00Z
    Publisher Institute of Basic Medical Sciences and Peking Union Medical College Hospital, Chinese Academy of Medical Sciences / Peking Union Medical College.
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  10. Article ; Online: Decarboxylative Nucleophilic Fluorination of Aliphatic Carboxylic Acids.

    Yu, Qian / Zhou, Donglin / Ma, Junjun / Song, Chunlan

    Organic letters

    2024  

    Abstract: Herein, we present a decarboxylative nucleophilic fluorination of carboxylic acids with a silver catalyst. This strategy enables the synthesis of a myriad of diverse and valuable fluorinated motifs under mild conditions, demonstrating good functional- ... ...

    Abstract Herein, we present a decarboxylative nucleophilic fluorination of carboxylic acids with a silver catalyst. This strategy enables the synthesis of a myriad of diverse and valuable fluorinated motifs under mild conditions, demonstrating good functional-group tolerance and utility in late-stage functionalization. In contrast to traditional electrophilic fluorination, this nucleophilic method utilizes a more readily available nucleophilic fluorinating reagent, providing substantial advantages in terms of cost efficiency, broad substrate scope, and functional-group compatibility.
    Language English
    Publishing date 2024-05-13
    Publishing country United States
    Document type Journal Article
    ISSN 1523-7052
    ISSN (online) 1523-7052
    DOI 10.1021/acs.orglett.4c01185
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top